Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02789397
Recruitment Status : Withdrawn (No funding for study.)
First Posted : June 3, 2016
Last Update Posted : March 10, 2020
Sponsor:
Information provided by (Responsible Party):
John M. Routes, Medical College of Wisconsin

Brief Summary:
This phase II study will assess the effect of a treatment combination of Rituximab and azathioprine in patients with Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) compared to placebo, based on change in lung function at 18 months compared to baseline. The researchers will also assess if the drugs improved quality of life.

Condition or disease Intervention/treatment Phase
Granulomatous and Lymphocytic Interstitial Lung Disease Drug: Rituximab (RTX) and Azathioprine (AZA) Drug: Placebos Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID)
Actual Study Start Date : May 2, 2016
Actual Primary Completion Date : March 6, 2018
Actual Study Completion Date : March 6, 2018


Arm Intervention/treatment
Active Comparator: Rituximab (RTX) and Azathioprine (AZA)
Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12. Azathioprine: Starting dose of azathioprine will be 50 mg and increased in 25 mg increments to a maximum dose of 150 mg or 2 mg/k/day (whichever is lowest) as tolerated. Azathioprine will be administered by mouth daily for 18 months.
Drug: Rituximab (RTX) and Azathioprine (AZA)
Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
Other Name: Truxima

Placebo Comparator: Placebo
IV placebo will be administered on the same schedule as Rituximab. Oral placebo will be administered by mouth daily for 18 months.
Drug: Placebos
IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
Other Name: Saline




Primary Outcome Measures :
  1. The effect of treatment with RTX/AZA in patients with GLILD compared to placebo, based on change in forced vital capacity (FVC) at 18 months compared to baseline. [ Time Frame: Baseline and 18 months ]
    Pulmonary Function Tests (PFTs) will be performed to measure lung volumes and airflow for evidence of restrictive and obstructive lung disease. PFTs are used to measure lung volumes and airflow for evidence of restrictive and obstructive lung disease. Measurements will be obtained by standard techniques following guidelines outlined by the American Thoracic Society. Spirometry, during screening, needs to be done pre- and post-bronchodilator. All subsequent spirometry is done post-bronchodilator. Diffusion capacity for carbon monoxide is always done post-bronchodilator. Spirometry will be performed to access the forced expiratory volume (FEV1) and forced vital capacity (FVC). Carbon monoxide diffusion capacity will be performed to assess gas exchange.


Secondary Outcome Measures :
  1. The effect of treatment with RTX/AZA relative to placebo on the changes over time in high-resolution CT scans of the chest. [ Time Frame: Baseline, six months, 12 months, 18 months, 24 months ]
    Non-contrast, low dose HRCT scans of the chest will be performed at the intervals and analyzed. Studies will be performed on high-end scanners (64 or above detector rows) capable of producing thin section (1-1.25mm) lung algorithm scans.

  2. Correlate changes in pulmonary function (FVC, FEV1, DLco) with extent of pulmonary fibrosis obtained on open lung biopsy. [ Time Frame: 24 months ]
    Pulmonary Function Tests (PFTs) will measure forced vital capacity, forced expiratory volume in one second, diffusing capacity of the lungs for carbon monoxide (DLCO) (e.g., DLco will be measured by the single-breath technique using a 10-second breath hold). Histopathologic abnormalities of lung tissue will be determined by open lung biopsy.

  3. Correlate changes in pulmonary function (FVC, FEV1, DLco) with high-resolution CT scan scores over time in the two randomized groups of patients. [ Time Frame: 24 months ]
    Pulmonary Function Tests (PFTs) will measure forced vital capacity, forced expiratory volume in one second, diffusing capacity of the lungs for carbon monoxide (DLCO) (e.g., DLco will be measured by the single-breath technique using a 10-second breath hold). These will be compared with high-resolution CT scan scores.

  4. Changes in FVC and HRCT of the chest (maintained for 6 months after completion of therapy in both randomized groups) [ Time Frame: Baseline, six months, 12 months, 18 months and 24 months ]
    Pulmonary Function Tests (PFTs) will measure forced vital capacity, forced expiratory volume in one second, diffusing capacity of the lungs for carbon monoxide (DLCO) (e.g., DLco will be measured by the single-breath technique using a 10-second breath hold). High-resolution CT scans will be performed.

  5. Incidence of lymphoma in patients treated with RTX/AZA or placebo over the time of enrollment in the study. [ Time Frame: 24 months ]
    Patients will be monitored with physical examinations, laboratory tests (CBC, auto diff, ALT, bilirubin, serum creatinine, platelets, comprehensive lymphocyte phenotype and cell sort).

  6. Changes in quality of life in the two randomized groups of patients as measured by SGRQ total score. [ Time Frame: Baseline, six months, 12 months, 18 months and 24 months ]
    Quality of life will be measured by the St. George's Respiratory Questionnaire (SGRQ), a pulmonary disease specific questionnaire measuring self-reported dyspnea symptoms and their relationship to activities of daily living and psychological functioning.

  7. Changes in quality of life in the two randomized groups of patients as measured by Karnofsky Performance Status Scale (KPS). [ Time Frame: Baseline, six months, 12 months, 18 months and 24 months ]
    Karnofsky Performance Status Scale (KPS) will be performed at baseline, six months, 12 months, 18 months and 24 months.

  8. Changes in quality of life in the two randomized groups of patients as measured by 6-minute Walking Test. [ Time Frame: Baseline, six months, 12 months, 18 months and 24 months ]
    The 6-minute Walking Test will performed at baseline, six months, 12 months, 18 months and 24 months.

  9. Dysregulated molecular pathway determined by performing whole transcriptome sequencing. [ Time Frame: 24 Months ]
    This will be done by performing whole transcriptome sequencing on GLILD, idiopathic pulmonary fibrosis (IPD), sarcoidosis and normal lung tissue.

  10. Lung transcriptome predicts response to RTX/AZA therapy (performing whole transcriptome sequencing on GLILD, IPD, sarcoidosis and normal lung tissue) and confirm that lung transcriptome predicts response to RTX/AZA therapy. [ Time Frame: 24 Months ]
    This will be done by performing whole transcriptome sequencing on GLILD, IPD, sarcoidosis and normal lung tissue.

  11. Peripheral blood biomarkers as indicators of GLILD disease activity. [ Time Frame: 24 Months ]
    The research team will examine blood specimens and evaluate Human Leukocyte Antigen - DR isotype (HLA-DR) negative and positive T cells.

  12. Presence of bacterial (16S rRNA), fungal (Internal Transcribed Spacer region/ITS) and viral sequences (unbiased high-throughput sequencing) in the lungs of GLILD patients. [ Time Frame: 24 Months ]
    This will be done by screening lung biopsies from patients with GLILD, idiopathic pulmonary fibrosis, pulmonary sarcoidosis, or no known pulmonary disease.

  13. Prevalence and abundance of bacterial, fungal and viral sequences. [ Time Frame: 24 Months ]
    This will be measured with quantitative PCR analysis of lung tissues obtained from patients with GLILD, idiopathic pulmonary fibrosis, pulmonary sarcoidosis or no known lung disease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

Age:

  • Patients must be 18 years of age or older.

Diagnosis:

  • Diagnosis of CVID in accordance with international criteria which includes: A) Serum immunoglobin G (IgG) at least 2 standard deviations below the age adjusted norm; B) Decreased serum immunoglobin A (IgA) and/or immunoglobin M (IgM); C) Age > 4 years.; D) Abnormal specific antibody production in response to immunization; E) Exclusion of secondary causes of hypogammaglobulinemia.
  • Diagnosis of GLILD based on histopathologic abnormalities of lung tissue obtained by open lung biopsy within 12 months of enrollment and confirmed by Pathology Core.

Performance Level:

  • Karnofsky Performance Status (KPS) ≥ 50%

Prior Therapy:

  • Patients must have fully recovered from the acute toxic effects of all prior therapy.
  • Systemic steroids need to be completed at least 60 days from the time of enrollment.

Organ Function:

  • Adequate Lung Function defined as:

    • FVC > 60 % predicted and

    • DLco > 35 % predicted

  • Adequate Bone Marrow Function defined as:

    • Peripheral absolute neutrophil count (ANC) ≥ 750/mm3 and

    • Platelet count ≥ 50,000/mm3

  • Adequate Hepatic Function as evidenced by:

    • Direct Bilirubin < 1.5 x upper limit of normal (ULN) for age
    • Serum glutamic pyruvic transaminase (SGPT) (ALT) < 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.
  • Adequate Renal Function as defined by a normal serum creatinine

Reproductive Function:

o Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.

  • Female patients with infants must agree not to breastfeed their infants while on this study.
  • Male and female patients of childbearing potential must agree to use an effective method of contraception approved by the investigator during the study.
  • Sexually active females of childbearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device (UD), surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment and for 6 months after the last dose of study therapy. Sexually active men must agree to use barrier contraceptive for the duration of treatment and for 6 months after the last dose of study therapy.

Regulatory Requirements

  • All patients must sign a written informed consent.
  • All institutional, FDA, and NIH requirements for human studies must be met.

EXCLUSION CRITERIA:

Infection:

  • Patients with uncontrolled infection are not eligible.
  • Patients with documented serious infection within 3 months of screening or opportunistic infection within 6 months of screening are not eligible.

Cardiac Function:

o Patients cannot be diagnosed with New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled hypertension.

Allergies:

o Known hypersensitivity to any of the components of RTX or AZA.

Current Therapy:

  • Systemic immunosuppressive medications including steroids.
  • Steroids can be used to prevent or to treat infusion-related RTX symptoms, but this should be used only prior to or immediately after the RTX infusion, and should not be continued beyond 3 days. The use of systemic steroids should be recorded.
  • Inhaled steroids are acceptable.

Previous Therapy:

o Previous treatment with RTX or AZA for GLILD.

Pregnant Females:

o Pregnant females will not be allowed to participate in this study.

Hepatic Disease:

o Known cirrhosis and/or portal hypertension.

Hepatitis B or Hepatitis C Infection:

  • All patients will be screened for Hepatitis B and C by polymerase chain reaction (PCR).
  • Hepatitis C positive as determined by PCR.
  • Hepatitis B Reactivation: Hepatitis B Reactivation is defined as Hepatitis B carrier patients with one of the following:

    • Positive hepatitis B e-antigen (HBe-Ag)
    • Quantitative hepatitis B Viral (HBV) DNA Load > 10^5 genomes/ml

Human Immunodeficiency Virus (HIV) 1 Positive:

o HIV 1 infection will be determined by PCR.

Homozygous Mutations:

o Patients with homozygous mutations of thiopurine methyltransferase (TPMT) will be excluded from the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02789397


Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: John M Routes, MD Medical College of Wisconsin
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: John M. Routes, Professor and Chief, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT02789397    
Other Study ID Numbers: PRO26723
First Posted: June 3, 2016    Key Record Dates
Last Update Posted: March 10, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by John M. Routes, Medical College of Wisconsin:
Granulomatous and lymphocytic interstitial lung disease (GLIILD)
common variable immunodeficiency
Rituximab
Azathioprine
primary immunodeficiency
GLIILD
CVID
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Interstitial
Immunologic Deficiency Syndromes
Common Variable Immunodeficiency
Immune System Diseases
Respiratory Tract Diseases
Rituximab
Azathioprine
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents